Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy
Our RT-QuIC protocol and analysis pipeline can distinguish between PD and MSA, and between MSA phenotypes. MSA α-Syn seeds induce faster propagation and exhibit higher aggregation kinetics than PD α-Syn, mirroring the biological differences observed in brain tissue. With further validation of these quantitative parameters, we propose that SAAs could advance from a yes/no diagnostic to a theranostic biomarker that could be utilised in developing therapeutics.
Authors
- Birger Victor Dieriks (ORCID: https://orcid.org/0000-0002-9392-3327)
- James A. Wiseman (ORCID: https://orcid.org/0000-0001-9880-1612)
- Glenda Margaret Halliday (ORCID: https://orcid.org/0000-0003-0422-8398)
- Clinton P. Turner (ORCID: https://orcid.org/0000-0002-2138-7633)
- Richard L. M. Faull (ORCID: https://orcid.org/0000-0003-3385-9498)
Institutions
- The University of Sydney (AU)
- University of Auckland (NZ)
- UNSW Sydney (AU)
- Brain Research New Zealand (NZ)
- Neuroscience Research Australia (AU)
Publication Details
- Journal
- Translational Neurodegeneration
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1186/s40035-025-00469-6
- Citations
- 10
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 13.89
Funders
- Neuroscience Research Australia
- Royal Society Te Apārangi
- Neurological Foundation of New Zealand
- National Health and Medical Research Council
- Health Research Council of New Zealand